Literature DB >> 29679177

Impact of the number of removed lymph nodes on recurrence-free survival in stage I ovarian clear cell carcinoma.

Yuji Takei1, Suzuyo Takahashi2, Shizuo Machida2, Akiyo Taneichi2, Takahiro Yoshiba2, Yoshifumi Takahashi2, Chikako Yoshida2, Yasushi Saga2, Shigeki Matsubara2, Hiroyuki Fujiwara2.   

Abstract

BACKGROUND: Although there have been several reports regarding the significance of staging lymphadenectomy for early stage ovarian clear cell carcinoma (CCC) patients, there have been few reports focusing on the number of removed lymph nodes. The aim of this study was to evaluate the impact of the number of removed lymph nodes on recurrence-free survival (RFS) in stage I ovarian CCC.
METHODS: The subjects were patients with ovarian CCC who underwent surgery between January 1988 and December 2013. Clinicopathological variables were obtained from the medical records retrospectively. Statistical analysis using Kaplan-Meier method, log-rank test, and Cox proportional hazards model was performed.
RESULTS: A total of 68 patients were entered into this study. The median number of removed lymph nodes was 56.5 (21-135). We calculated that the cutoff value of the number of removed lymph nodes for predicting recurrence was 35. RFS of the group with ≥ 35 removed lymph nodes was significantly better than that of the group with < 35 removed lymph nodes (p = 0.001). Similarly, RFS of stage IA and PS 0 or 1 was significantly better than that of stage IC (p = 0.029) and PS 2 or 3 (p = 0.001), respectively. Multivariate analysis revealed that the number of removed lymph nodes, stage, and PS was independent predictors for RFS.
CONCLUSIONS: This study showed that the number of removed lymph nodes ≥ 35 was an independent predictor for improved RFS for stage I ovarian CCC. Sufficient lymphadenectomy may improve prognosis for stage I ovarian CCC.

Entities:  

Keywords:  Clear cell carcinoma; Ovarian cancer; Recurrence-free survival; Removed lymph nodes

Mesh:

Year:  2018        PMID: 29679177     DOI: 10.1007/s10147-018-1280-9

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  17 in total

1.  The impact of complete surgical staging upon survival in early-stage ovarian clear cell carcinoma: a multi-institutional retrospective study.

Authors:  Masashi Takano; Toru Sugiyama; Nobuo Yaegashi; Mitsuaki Suzuki; Hiroshi Tsuda; Satoru Sagae; Yasuhiro Udagawa; Kazuo Kuzuya; Junzo Kigawa; Satoshi Takeuchi; Hitoshi Tsuda; Takuya Moriya; Yoshihiro Kikuchi
Journal:  Int J Gynecol Cancer       Date:  2009-11       Impact factor: 3.437

2.  Colorectal cancer statistics, 2017.

Authors:  Rebecca L Siegel; Kimberly D Miller; Stacey A Fedewa; Dennis J Ahnen; Reinier G S Meester; Afsaneh Barzi; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2017-03-01       Impact factor: 508.702

3.  Nedaplatin and irinotecan combination therapy is equally effective and less toxic than cisplatin and irinotecan for patients with primary clear cell adenocarcinoma of the ovary and recurrent ovarian carcinoma.

Authors:  Shizuo Machida; Tomomi Sato; Hiroyuki Fujiwara; Yasushi Saga; Yuji Takei; Akiyo Taneichi; Hiroaki Nonaka; Mitsuaki Suzuki
Journal:  Oncol Lett       Date:  2012-08-06       Impact factor: 2.967

4.  Anatomical study of para-aortic and pelvic lymph nodes in gynecologic malignancies.

Authors:  P B Panici; G Scambia; G Baiocchi; G Matonti; A Capelli; S Mancuso
Journal:  Obstet Gynecol       Date:  1992-04       Impact factor: 7.661

5.  Pelvic and aortic lymph node metastasis in epithelial ovarian cancer.

Authors:  Augusto Pereira; Javier F Magrina; Victoria Rey; Manuel Cortes; Paul M Magtibay
Journal:  Gynecol Oncol       Date:  2007-02-23       Impact factor: 5.482

6.  A feasibility study of paclitaxel and carboplatin therapy in Japanese patients with epithelial ovarian cancer.

Authors:  Yuji Takei; Mitsuaki Suzuki; Michitaka Ohwada; Yasushi Saga; Takahiro Kohno; Shizuo Machida; Ikuo Sato
Journal:  Oncol Rep       Date:  2003 Jul-Aug       Impact factor: 3.906

7.  Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy.

Authors:  T Sugiyama; T Kamura; J Kigawa; N Terakawa; Y Kikuchi; T Kita; M Suzuki; I Sato; K Taguchi
Journal:  Cancer       Date:  2000-06-01       Impact factor: 6.860

8.  Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial.

Authors:  Noriyuki Katsumata; Makoto Yasuda; Fumiaki Takahashi; Seiji Isonishi; Toshiko Jobo; Daisuke Aoki; Hiroshi Tsuda; Toru Sugiyama; Shoji Kodama; Eizo Kimura; Kazunori Ochiai; Kiichiro Noda
Journal:  Lancet       Date:  2009-09-18       Impact factor: 79.321

9.  Prevalence and prognostic impact of lymphadenectomy and lymph node metastasis in clinically early-stage ovarian clear cell carcinoma.

Authors:  Haider Mahdi; Mehdi Moslemi-Kebria; Kimberly L Levinson; Anar Gojayev; David Lockhart; Rouba Ali-Fehmi; Adnan R Munkarah
Journal:  Int J Gynecol Cancer       Date:  2013-09       Impact factor: 3.437

10.  Staging Lymphadenectomy in Patients With Clear Cell Carcinoma of the Ovary.

Authors:  Jennifer J Mueller; Marie Holzapfel; Chan H Han; Kevin Santos; Camille Gunderson; Kathleen Moore; Britt Erickson; Charles A Leath; Elena Diaz; Christine Walsh; Stephanie L Wethington; Sheila Z Dejbakhsh; Richard R Barakat; Ginger J Gardner; David M Hyman; Robert A Soslow; Mario M Leitao
Journal:  Int J Gynecol Cancer       Date:  2016-01       Impact factor: 3.437

View more
  5 in total

Review 1.  Rethinking of treatment strategies and clinical management in ovarian clear cell carcinoma.

Authors:  Kazuaki Takahashi; Masataka Takenaka; Ayako Kawabata; Nozomu Yanaihara; Aikou Okamoto
Journal:  Int J Clin Oncol       Date:  2020-01-27       Impact factor: 3.402

2.  Validity of the 2014 FIGO Stage IIIA1 Subclassification for Ovarian, Fallopian Tube, and Peritoneal Cancers.

Authors:  Ayumu Matsuoka; Shinichi Tate; Kyoko Nishikimi; Masami Iwamoto; Satoyo Otsuka; Makio Shozu
Journal:  In Vivo       Date:  2022 Sep-Oct       Impact factor: 2.406

3.  Development and validation of Nomograms for predicting overall survival and Cancer-specific survival in patients with ovarian clear cell carcinoma.

Authors:  Qian Chen; Shu Wang; Jing-He Lang
Journal:  J Ovarian Res       Date:  2020-10-17       Impact factor: 4.234

4.  Therapeutic Role of Retroperitoneal Lymphadenectomy in 170 Patients With Ovarian Clear Cell Cancer.

Authors:  Wen Gao; Peipei Shi; Haiyan Sun; Meili Xi; Wenbin Tang; Sheng Yin; Jiarong Zhang
Journal:  Front Oncol       Date:  2022-01-13       Impact factor: 6.244

5.  Systematic Pelvic and Para-Aortic Lymphadenectomy During Fertility-Sparing Surgery in Patients With Early-Stage Epithelial Ovarian Cancer: A Retrospective Study.

Authors:  Tingting Li; Ya Liu; Sixia Xie; Hongjing Wang
Journal:  Front Oncol       Date:  2022-06-17       Impact factor: 5.738

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.